Literature DB >> 26140435

N‑terminal pro‑B-type natriuretic peptide as a marker of hypervolemia and predictor of increased mortality in patients on hemodialysis.

Krzysztof Schwermer, Krzysztof Hoppe, Dorota Radziszewska, Patrycja Kłysz, Peter Sawatiuk, Justin Nealis, Małgorzata Kałużna, Jolanta Kaczmarek, Ewa Baum, Bengt Lindholm, Krzysztof Pawlaczyk, Andrzej Oko.   

Abstract

INTRODUCTION: N‑terminal pro‑B‑type natriuretic peptide (NT‑proBNP) is an established biomarker of heart failure in the general population. However, its diagnostic value is unclear in hemodialysis (HD) patients owing to renal insufficiency.
OBJECTIVES: The aim of the study was to establish the usefulness of NT‑proBNP for hydration assessment and the relation of NT‑proBNP to the nutritional state and prognosis of survival. PATIENTS AND METHODS: In 321 HD patients (206 men; mean age, 65.1 ±21.4 years), we assessed NT‑proBNP levels, overhydration (OHBIA), and the indices of the nutritional state (using a bioimpedance analysis [BIA]) in relation to cardiac troponin T (cTnT), hemoglobin, albumin, total cholesterol (TC), and C‑reactive protein (CRP) levels. The efficacy of HD was assessed using Kt/V, weekly HD dose, and HD session ultrafiltration. The cohort was divided into NT‑proBNP quartiles. Patients with 2 NT‑proBNP measurements were categorized also into change‑over‑time subgroups. A follow‑up lasted for a median period of 23.8 ±26.3 months.
RESULTS: Relative OHBIA increased across the NT‑proBNP quartiles (Q1/Q2/Q3/Q4, 1.31% ±2.56%/2.06% ±2.35%/2.92% ±2.97%/4.62% ±4.22%; P <0.0001). NT‑proBNP was also closely associated with other OH parameters. In addition, there was a significant correlation between NT‑proBNP and cTnT (r = 0.55; P <0.0001). Body mass index (BMI) and fat tissue index (FTI) decreased across the quartiles (BMI, 28.5 ±7.7/26.0 ±6.6/25.8 ±5.4/23.7 ±5.5 kg/m2; FTI, 14.4 ±9.0/14.1 ±7.3/12.3 ±6.8/11.6 ±6.1; P <0.001). The highest albumin level was present in Q1 (4.10 ±0.63/3.99 ±0.51/3.90 ±0.62/3.97 ±0.78 g/dl; P = 0.006). The TC level was the lowest in Q4 (190 ±60/169 ±56/173 ±51/153 ±56 mg/dl; P = 0.002). The hemoglobin level decreased across the quartiles (11.44 ±1.25/11.15 ±2.50/10.79 ±1.51/10.45 ±1.67 g/dl; P = 0.0006). The differences in CRP levels and HD‑related parameters were nonsignificant. During the follow‑up, 97 deaths were recorded (11/26/21/39, P <0.0001).
CONCLUSIONS: NT‑proBNP seems to be a useful biomarker of hypervolemia in HD patients. Nevertheless, it has to be interpreted with regard to the patient's individual residual renal function and cardiovascular status.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26140435     DOI: 10.20452/pamw.2969

Source DB:  PubMed          Journal:  Pol Arch Med Wewn


  5 in total

Review 1.  Do Natriuretic Peptide Measurements Provide Insights into Management of End-Stage Renal Disease Patients Undergoing Dialysis?

Authors:  Thanat Chaikijurajai; Hernan Rincon Choles; W H Wilson Tang
Journal:  Curr Heart Fail Rep       Date:  2020-09-17

2.  Ghrelin and acyl ghrelin levels are associated with inflammatory and nutritional markers and with cardiac and vascular dysfunction parameters in hemodialysis patients.

Authors:  Crina Claudia Rusu; Simona Racasan; Diana Moldovan; Alina Potra; Dacian Tirinescu; Cristian Budurea; Remus Orasan; Ioan Mihai Patiu; Cosmina Bondor; Dan Vladutiu; Dan Delean; Alexandra Danu; Ina Maria Kacso
Journal:  Int Urol Nephrol       Date:  2018-07-13       Impact factor: 2.370

3.  Brain natriuretic peptide reflects individual variation in hydration status in hemodialysis patients.

Authors:  Jenny Stenberg; Jan Melin; Magnus Lindberg; Hans Furuland
Journal:  Hemodial Int       Date:  2019-03-07       Impact factor: 1.812

4.  Influence of dry weight reduction on anemia in patients undergoing hemodialysis.

Authors:  Yinghui Deng; Hua Liu; Na Lin; Lina Ma; Wenjing Fu
Journal:  J Int Med Res       Date:  2019-09-17       Impact factor: 1.671

Review 5.  N-terminal Pro-B-Type Natriuretic Peptide and Malnutrition in Patients on Hemodialysis.

Authors:  Jacques Ducros; Laurent Larifla; Henri Merault; Valérie Galantine; Valérie Bassien-Capsa; Lydia Foucan
Journal:  Int J Nephrol       Date:  2020-03-05
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.